Novo Nordisk on Tuesday received a broker downgrade, with the analysts arguing that its status as a duopoly in both diabetes and weight loss are under threat.
FlashNews:
Ozempic maker Novo Nordisk gets another downgrade. The end’s in sight for its duopoly status, says TD Cowen.
ROA and and wander Unveil Their Second Collaborative Collection
Hyperliquid’s tokenized futures hit $1.2B as traders bet on oil, stocks
The ‘big brother’ helping Arteta’s Arsenal ‘over the line’
Kaine: Trump calling Iran war an ‘excursion’ is ‘deeply disrespectful’ to service members
The Best Things to Do in Rome Are Some of the Eternal City’s Oldest
Tomás Saraceno and Indigenous communities build art complex in Argentine salt flats
Sweat Decks Simplifies Backyard Spa Construction with Full-Service Design and Installation
AI Speech Therapist Helps Thousands of Children Practice at Home Every Day
Spawned Launches Solana Tokens in Minutes, No Dev Team Required
FarrierIQ Brings Mobile Business Management to Professional Farriers
Hairline AI Brings Clinical-Grade Hair Loss Assessment to the Phone
Ballroom AI Lets Event Vendors Keep 100 Percent of Their Revenue While Winning More Bookings
AI Platform Lets Tree Service Companies Quote Jobs From Photos in Minutes Instead of Days
AI Platform Predicts Septic Tank Pumping Needs, Helping Service Companies Cut Fuel Costs and Prevent Emergencies
PollenOps Introduces Platform Designed to Support Large-Scale Commercial Beekeeping Operations
CricketOps Launches Operating Platform for the Growing Insect Protein Farming Industry
CricketOps Launches Operating Platform for the Growing Insect Protein Farming Industry
CricketOps Launches Operating Platform for the Growing Insect Protein Farming Industry
Home » Ozempic maker Novo Nordisk gets another downgrade. The end’s in sight for its duopoly status, says TD Cowen.